Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 18, 2008

Roche Inks Deal Worth $774M for Rights to Anticancer Agent

  • ThromboGenics and BioInvent inked a deal with Roche covering development and commercialization of TB-403, their jointly developed Phase I anticancer agent. In exchange for a worldwide exclusive license to TB-403, Roche will make an upfront payment of $77.41M (EUR50 million).

    In addition, ThromboGenics and BioInvent could potentially receive up to $696.89M (EUR450M) based on the successful completion of a series of development and commercial milestones for multiple indications, as well as double-digit royalties on potential product sales, including any backup antibodies based on inhibition of PlGF. TB-403 was in-licensed by ThromboGenics from the Flanders Institute for Biotechnology where the therapeutic potential of anti-PlGF agents to treat cancer was first developed.

    ThromboGenics will receive 60% and BioInvent 40% of the revenue from the deal.

    Related Links:

    ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III) 

    Flanders Striving to Attract Biotechnology



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »